Allergy Therapeutics (LON:AGY) Shares Cross Below 200-Day Moving Average – Here’s Why

Allergy Therapeutics plc (LON:AGY)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 10.44 and traded as low as GBX 7.22. Allergy Therapeutics shares last traded at GBX 7.48, with a volume of 131,015 shares.

Allergy Therapeutics Stock Performance

The company has a market capitalization of £473.67 million, a P/E ratio of -7.71, a PEG ratio of -30.70 and a beta of 0.85. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The stock has a fifty day moving average of GBX 9.36 and a 200 day moving average of GBX 10.44.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. The company had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. As a group, equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.